Accessibility Menu
 
Marker Therapeutics logo

Marker Therapeutics

(NASDAQ) MRKR

Current Price$1.43
Market Cap$23.84M
Since IPO (2002)-100%
5 Year-95%
1 Year+30%
1 Month-8%

Marker Therapeutics Financials at a Glance

Market Cap

$23.84M

Revenue (TTM)

$2.09M

Net Income (TTM)

$10.90M

EPS (TTM)

$-0.67

P/E Ratio

-2.12

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$1.43

Volume

56,247.667

Open

$1.40

Previous Close

$1.43

Daily Range

$1.40 - $1.47

52-Week Range

$0.81 - $4.07

MRKR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Marker Therapeutics

Industry

Biotechnology

Employees

5

CEO

Juan F. Vera, MD

Headquarters

Houston, TX 77027, US

MRKR Financials

Key Financial Metrics (TTM)

Gross Margin

-99%

Operating Margin

-6%

Net Income Margin

-5%

Return on Equity

-77%

Return on Capital

-90%

Return on Assets

-63%

Earnings Yield

-47.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.84M

Shares Outstanding

16.67M

Volume

56.25K

Avg. Volume

115.31K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$12.89M

EBITDA

$12.44M

Operating Cash Flow

$12.01T

Capital Expenditure

$0.00

Free Cash Flow

$12.01T

Cash & ST Invst.

$16.07T

Total Debt

$0.00

Marker Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$23.84M

N/A

Market Cap/Employee

$4.77M

N/A

Employees

5

N/A

Net Income

$3.18M

+28.5%

EBITDA

$4.07M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$14.92M

+8.9%

Accounts Receivable

$1.38M

-44.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-62.50%

N/A

Return on Invested Capital

-89.55%

N/A

Free Cash Flow

$1.40M

+74.5%

Operating Cash Flow

$1.40M

+74.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNSESensei Biotherapeutics, Inc.
$18.01+2.56%
PHIOPhio Pharmaceuticals Corp.
$1.11+1.83%
COCPCocrystal Pharma, Inc.
$1.17+3.57%
CLRBCellectar Biosciences, Inc.
$3.27+3.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.40+0.05%
FFord Motor Company
$14.79+0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$78.80+0.02%
BBBlackBerry
$7.92+0.19%

Questions About MRKR

What is the current price of Marker Therapeutics?

Marker Therapeutics is trading at $1.43 per share.

What is the 52-week range for Marker Therapeutics?

Over the past 52 weeks, Marker Therapeutics has traded between $0.81 and $4.07.

How much debt does Marker Therapeutics have?

As of the most recent reporting period, Marker Therapeutics reported total debt of N/A.

How much cash does Marker Therapeutics have on hand?

Marker Therapeutics reported $15.64M in cash and cash equivalents in its most recent financial results.

What is Marker Therapeutics’s dividend yield?

Marker Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.